tiprankstipranks
Agios Pharma (AGIO)
NASDAQ:AGIO
Want to see AGIO full AI Analyst Report?

Agios Pharma (AGIO) Stock Statistics & Valuation Metrics

689 Followers

Total Valuation

Agios Pharma has a market cap or net worth of $1.67B. The enterprise value is $1.57B.
Market Cap$1.67B
Enterprise Value$1.57B

Share Statistics

Agios Pharma has 59,471,607 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding59,471,607
Owned by Insiders1.11%
Owned by Institutions0.53%

Financial Efficiency

Agios Pharma’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is -38.18%.
Return on Equity (ROE)-0.35
Return on Assets (ROA)-0.32
Return on Invested Capital (ROIC)-38.18%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee111.17K
Profits Per Employee-849.34K
Employee Count486
Asset Turnover0.04
Inventory Turnover0.35

Valuation Ratios

The current PE Ratio of Agios Pharma is ―. Agios Pharma’s PEG ratio is 0.02.
PE Ratio
PS Ratio29.21
PB Ratio1.32
Price to Fair Value1.32
Price to FCF-4.18
Price to Operating Cash Flow-4.35
PEG Ratio0.02

Income Statement

In the last 12 months, Agios Pharma had revenue of 54.03M and earned -412.78M in profits. Earnings per share was -7.12.
Revenue54.03M
Gross Profit42.51M
Operating Income-472.13M
Pretax Income-413.80M
Net Income-412.78M
EBITDA-466.95M
Earnings Per Share (EPS)-7.12

Cash Flow

In the last 12 months, operating cash flow was -380.41M and capital expenditures -4.32M, giving a free cash flow of -384.73M billion.
Operating Cash Flow-380.41M
Free Cash Flow-384.73M
Free Cash Flow per Share-6.47

Dividends & Yields

Agios Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.90
52-Week Price Change-6.04%
50-Day Moving Average29.93
200-Day Moving Average33.79
Relative Strength Index (RSI)69.76
Average Volume (3m)902.68K

Important Dates

Agios Pharma upcoming earnings date is Jul 30, 2026, TBA (Confirmed).
Last Earnings DateApr 29, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date

Financial Position

Agios Pharma as a current ratio of 11.46, with Debt / Equity ratio of 3.22%
Current Ratio11.46
Quick Ratio11.06
Debt to Market Cap0.03
Net Debt to EBITDA0.06
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Agios Pharma has paid -1.02M in taxes.
Income Tax-1.02M
Effective Tax Rate<0.01

Enterprise Valuation

Agios Pharma EV to EBITDA ratio is -3.32, with an EV/FCF ratio of -4.11.
EV to Sales28.71
EV to EBITDA-3.32
EV to Free Cash Flow-4.11
EV to Operating Cash Flow-4.16

Balance Sheet

Agios Pharma has $737.04M in cash and marketable securities with $35.74M in debt, giving a net cash position of $701.29M billion.
Cash & Marketable Securities$737.04M
Total Debt$35.74M
Net Cash$701.29M
Net Cash Per Share$11.79
Tangible Book Value Per Share$20.58

Margins

Gross margin is 82.07%, with operating margin of -873.87%, and net profit margin of -764.01%.
Gross Margin82.07%
Operating Margin-873.87%
Pretax Margin-765.89%
Net Profit Margin-764.01%
EBITDA Margin-864.28%
EBIT Margin-873.87%

Analyst Forecast

The average price target for Agios Pharma is $38.29, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$38.29
Price Target Upside8.95% Upside
Analyst ConsensusModerate Buy
Analyst Count8
Revenue Growth Forecast78.34%
EPS Growth Forecast-161.91%

Scores

Smart Score4
AI Score